CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

PAH Clinical Trial

Official title:

A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04053543
• Other study ID #: CXA-10-2302
• Status: Terminated
• Phase: Phase 2
• Start date: August 9, 2019
• Est. completion date: August 12, 2020

Study information

• Verified date: August 2020
• Source: Complexa, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.

Description:

This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.

The study will be performed in approximately 50 study centers across the United States and the United Kingdom, which participated in CXA-10-301. Approximately 96 subjects who completed treatment in CXA-10-301 will be eligible to participate in this OLE study, after completing all Visit 9 (Day 1 and Day 2) assessments in CXA-10-301.

Study participation for each subject will last up to approximately 6.5 months. The study will consist of a 6 month open-label treatment period and require 5 clinic visits and 1 telephone visit, including the Baseline Visit completed simultaneously with Visit 9 CXA-10-301, plus a follow-up visit approximately 2 weeks following the last dose of CXA-10.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 33
• Est. completion date: August 12, 2020
• Est. primary completion date: August 12, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Evidence of a personally signed and dated informed consent document indicating subject has been informed of all pertinent aspects of the study prior to initiation of any study-required procedures.

2. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

3. Has completed the CXA-10-301 study and demonstrated compliance with study medication administration and study requirements.

4. If receiving simvastatin-containing products: simvastatin (Zocor), Vytorin, or any other combination therapy containing simvastatin, simvastatin dose does not exceed 20 mg/day.

5. Currently receiving no more than three of the following previously approved PAH therapies: phosphodiesterase type 5 (PDE-5) inhibitors, endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) stimulator, prostanoids, prostacyclin receptor agonists.

6. Women of childbearing potential and males with partners of childbearing potential must agree to use a reliable method of contraception while taking study medication.

Exclusion Criteria:

1. Severe hypotension defined by systolic blood pressure <90 mmHg from sitting blood pressure measurement at Baseline.

2. Hypertensive defined by >160 mmHg systolic or >110 mmHg diastolic from sitting blood pressure measurement at Baseline.

3. QTcF on supine ECGs at Baseline (Visit 1) of >500 msec.

4. Acute myocardial infarction or acute coronary syndrome (ST-Elevation Myocardial Infarction [STEMI], Non STEMI [NSTEMI] and or unstable angina) within the last 90 days prior to Baseline.

5. Recent cerebrovascular accident/transient ischemic attack (CVA/TIA) within the last 90 days prior to Baseline.

6. Recent hospitalization for left heart failure within the last 90 days prior to Baseline.

7. Clinically significant aortic or mitral valve disease defined as greater than mild regurgitation or mild stenosis; pericardial constriction; restrictive or constrictive cardiomyopathy; left ventricular dysfunction (LVEF < 50%); left ventricular outflow obstruction; symptomatic coronary artery disease; autonomic hypotension; or fluid depletion, in the opinion of the investigator.

8. Chronic atrial fibrillation and life-threatening cardiac arrhythmias.

9. Personal or family history of congenital prolonged QTc syndrome or sudden unexpected death due to a cardiac reason.

10. Clinically significant anemia in the opinion of the investigator that precludes enrollment into this study, or Hb <9 gm/dl.

11. Severe hepatic impairment (Child-Pugh class C with or without cirrhosis) at Baseline or active chronic hepatitis.

12. Received intravenous inotropes within 2 weeks prior to Baseline (e.g. dopamine, dobutamine).

13. History of angina pectoris or other condition that was treated with long or short acting nitrates <12 weeks of Baseline.

14. History of herbal or natural medication use (including fish oil) within 2 weeks or 5 half-lives, whichever is longer, prior to Baseline.

15. Received prednisone at doses > 15 mg/ day or changes in immunosuppressive medications <12 weeks prior to Baseline.

16. Currently taking a drug that may affect the assay measurement of serum creatinine (e.g. cimetidine, Bactrim, Pyridium). A list is provided in Appendix H.

21. Newly prescribed drug or increased dose of an existing drug that is known to prolong the QTc interval and has been associated with Torsades de Pointes (TdP) identified in the CredibleMeds.org website list as known risk (KR) of TdP.

Note: Stable doses of drugs classified as conditional risk (CR) of TdP or possible risk (PR) of TdP are permitted (i.e., subject has received the same dose and regimen for at least 30 days prior to Baseline with no anticipated changes to the dose or regimen during the course of the study).

22. Currently taking dimethyl fumarate (Tecfidera™).

23. Any of the following laboratories abnormal and unresolved in CXA-10-301:

1. Absolute lymphocyte counts < 0.5 x 109 cells/L.

2. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3.0X upper limit of normal (ULN), alkaline phosphatase (AP) > 2X ULN of liver origin, and total bilirubin >2X ULN. If all liver function tests (LFTs) are within normal limits (WNL) and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted to evaluate for Rotor's/Gilbert's Syndrome. Subjects with Rotor's/Gilbert's Syndrome may be enrolled.

3. eGFR < 30 mL/min/1.73 m2 (estimated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] Creatinine/Cystatin C 2012 algorithm) at Baseline.

24. Females who are pregnant or breastfeeding, or who are trying to conceive. 25. Recent (within 1 year) history of abusing alcohol or illicit drugs. 26. History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, or other malignancies (such as thyroid or testicular) that have been curatively treated and with no evidence of disease for at least 3 years or prostate cancer who is not currently or expected, during the study, to undergo radiation therapy, chemotherapy, and/or surgical intervention, or to initiate hormonal treatment.

Exception: subjects with history of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ are eligible for enrollment.

27. Cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, central nervous system or psychiatric disease that, in the opinion of the investigator, may adversely affect the safety of the subject and/or efficacy of the investigational product or severely limit the lifespan of the subject other than the condition being studied.

28. Clinically significant hyperthyroidism or hypothyroidism not adequately treated.

29. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non- compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures).

30. Known hypersensitivity to CXA-10, the metabolites, or formulation excipients.

31. Treatment with any investigational drug (other than CXA-10) or device within 30 days or 5 half-lives (whichever is longer) prior to Baseline (this includes investigational formulations of marketed products, inhaled and topical drugs), or plans to participate in an investigational drug or device study at any time during this study.

Related Conditions & MeSH terms

• Hypertension
• PAH

Intervention

Drug:
• CXA-10
(10-nitro-9(E)-octadec-9enoic acid)

Locations

Country	Name	City	State
United Kingdom	Golden Jubilee National Hospital	Glasgow
United Kingdom	Hammersmith Hospital	London
United Kingdom	Royal Brompton	London
United Kingdom	Royal Free	London
United Kingdom	Freeman Hospital	Newcastle Upon Tyne
United Kingdom	Royal Hallamshire Hospital	Sheffield
United States	Anaheim Clinical Trials, LLC	Anaheim	California
United States	University of Alabama	Birmingham	Alabama
United States	University of Virginia School of Medicine	Charlottesville	Virginia
United States	University of Chicago	Chicago	Illinois
United States	Christ Hospital-Lindner Research Center	Cincinnati	Ohio
United States	Cleveland Clinic	Cleveland	Ohio
United States	The Ohio State University	Columbus	Ohio
United States	UT Southwestern	Dallas	Texas
United States	National Jewish Health	Denver	Colorado
United States	Duke University	Durham	North Carolina
United States	Texas Tech	El Paso	Texas
United States	Inova Medical Campus	Falls Church	Virginia
United States	University of Florida Health	Gainesville	Florida
United States	Houston Methodist	Houston	Texas
United States	Indiana University	Indianapolis	Indiana
United States	Mayo Clinic	Jacksonville	Florida
United States	University of Kansas	Kansas City	Kansas
United States	University of California San Diego	La Jolla	California
United States	University of Miami	Miami	Florida
United States	Froedert Medical College of Wisconsin	Milwaukee	Wisconsin
United States	University of Minnesotta	Minneapolis	Minnesota
United States	Vanderbuilt University	Nashville	Tennessee
United States	NYU Langone Medical Center	New York	New York
United States	Sentara Medical Group	Norfolk	Virginia
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Allegheny General Hospital	Pittsburgh	Pennsylvania
United States	Washington University and Barnes Jewish Hospital	Saint Louis	Missouri
United States	University of California San Francisco	San Francisco	California
United States	University of Arizona	Tucson	Arizona
United States	George Washington Medical Faculty Associates	Washington	District of Columbia
United States	Washington Hospital (Medstar)	Washington	District of Columbia

Sponsors (4)

Lead Sponsor	Collaborator
Complexa, Inc.	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), Innovative Analytics, Medpace, Inc.

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of AEs	Adverse events occurring during the treatment period	6 months
Primary	Changes in respiration	Change from baseline values at each post-baseline time point	6 months
Primary	Changes in heart rate	Change from baseline values at each post-baseline time point	6 months
Primary	Changes in blood pressure	Change from baseline values at each post-baseline time point	6 months
Secondary	PAH-specific medication changes	Addition or removal of PAH-specific medications, including any dose changes	6 months
Secondary	6 Minute Walk Distance	Change from baseline in 6-minute walk distance (6MWD)	6 months
Secondary	Who Classification of Functional Status	Change from baseline in WHO Classification of Functional Status of Patients with PH	6 months
Secondary	Clinical worsening	Death from any cause, hospitalization for worsening PAH, Disease progression, unsatisfactory long-term clinical response	6 months